LENZ Therapeutics Inc Total Assets
LENZ Therapeutics Inc total assets. Based on the latest financial reports, LENZ Therapeutics Inc (LENZ) holds total assets worth $236.60 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see LENZ Therapeutics Inc (LENZ) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of LENZ Therapeutics Inc (2019–2025)
Total assets of LENZ Therapeutics Inc from 2019 to 2025. This chart illustrates how LENZ Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See LENZ Therapeutics Inc (LENZ) stock price for real-time trading data and today's change.
LENZ Therapeutics Inc - Asset Composition Analysis
LENZ Therapeutics Inc Total Assets Breakdown (December 2025)
LENZ Therapeutics Inc total assets breakdown as of December 2025. LENZ Therapeutics Inc's total assets of $236.60 Million consist of 98.5% current assets and 1.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.2% |
| Accounts Receivable | $2.43 Million | 0.8% |
| Inventory | $2.94 Million | 1.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how LENZ Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of LENZ Therapeutics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LENZ Therapeutics Inc's current assets represent 98.5% of total assets in 2025, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 8.2% of total assets in 2025, down from 100.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 1.0% of total assets.
LENZ Therapeutics Inc Competitors by Total Assets
Key competitors of LENZ Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
LENZ Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.55 | 20.54 | 35.60 |
| Quick Ratio | 13.31 | 20.54 | 35.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $216.07 Million | $203.20 Million | $389.96 Million |
LENZ Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between LENZ Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 42.1% |
| Total Assets | $305.88 Million |
| Market Capitalization | $108.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values LENZ Therapeutics Inc's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: LENZ Therapeutics Inc's assets grew by 42.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for LENZ Therapeutics Inc (2019–2025)
The table below shows the annual total assets of LENZ Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $305.88 Million | +42.07% |
| 2024-12-31 | $215.30 Million | +205.93% |
| 2023-12-31 | $70.38 Million | +49.89% |
| 2022-12-31 | $46.95 Million | +156.07% |
| 2021-12-31 | $18.34 Million | -18.74% |
| 2020-12-31 | $22.56 Million | +375966.67% |
| 2019-12-31 | $6.00K | -- |
About LENZ Therapeutics Inc
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2… Read more